Eliquis Kit
Product Images NDC 0003-3764

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 0003-3764). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

FDA Label Image

Eliquis 2.5 mg X 60s Bottle (Eliquis 2pt5mg 60slbl)

Eliquis 2.5 mg X 60s Bottle (Eliquis 2pt5mg 60slbl)
This is a description of a medication called Eliquis in tablet form, containing 2.5mg of apixaban. Each bottle contains 60 tablets and the NDC code is 0003-0893-21. The instructions and dosages must be read on the package insert. The tablets should be stored at temperatures ranging from 20°C to 25°C. This medication is produced and marketed by Bristol-Myers Squibb Company.*
FDA Label Image

Eliquis 5 mg X 60s Bottle (Eliquis 5mg 60slbl)

Eliquis 5 mg X 60s Bottle (Eliquis 5mg 60slbl)
Eliquis is a medication available in the form of tablets that contain 5mg apixaban. It is a prescription-only medication that is distributed by Bristol-Myers Squibb Company in Princeton, USA, and Pizer Inc in NY, USA. The standard dosage of the medication should be taken as per the information provided in the package insert. The tablets should be stored between 20 to 25 degrees Celsius, and excursions between 15 to 50 degrees Celsius are allowed. Furthermore, it should not be used or taken if broken or missing.*
FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)
This is a table with data from a study comparing the effects of Apixaban and Warfarin on different subgroups of patients. The table shows the number of events and the number of patients (% per year). The subgroups are divided by different categories such as age, sex, weight, previous stroke or TIA, presence of diabetes, and CHADS, score among others. The risk ratio adjusted with 95% confidence intervals is also reported. However, the specific details and conclusions from the study are not available.*
FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)
The text describes the fold-change and 90% confidence interval for drug interactions with various inhibitors and inducers of P-gp and CYP3A4 enzymes. It includes the specific dosages of each medication and their effect on AUC (area under the curve). The drugs tested include Ketoconazole, Glarithromycin, Diltiazem, Naproxen, and Rifampin. The results show changes in AUC relative to a reference drug.*
FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

FDA Label Image

Eliquis 5 mg X 74 Starter Pack Carton (Eliquis Starterpack 5mg74s Carton)

Eliquis 5 mg X 74 Starter Pack Carton (Eliquis Starterpack 5mg74s Carton)
This is a description of a Starter Pack for Eliquis (Apixaban) tablets that contains two wallets and is intended for use by the Westman and Pimonany Eolian. The pack includes 30-day supply of Eliquis tablets, with 5mg per tablet.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.